Searchable abstracts of presentations at key conferences in endocrinology

ea0022p240 | Clinical case reports and clinical practice | ECE2010

Synergic effect of Cabergoline in acromegaly treated with somatostatin analogues. Report of two cases

Paja Miguel , Perez-Yeboles Josu , Lizarraga Aitzol , Moreno Cristina , Isusquiza Ana , Elorza J Ramon

Current treatment for acromegaly includes dopamine agonists (DA), somatostatin receptor ligands (SRL) and GH receptor antagonists (GHRA). DA in monotherapy, is less than 10% effective achieving control of the disease, and its efficacy in addition to ongoing SRL is less studied, without obvious determining factors of response. We report 2 operated patients with incomplete response to SRL and to whom Cabergoline addition led to disease control.Case 1: A ma...

ea0035p1118 | Thyroid Cancer | ECE2014

Clinical and biochemical characteristics of papillary thyroid cancer according to the presence of BRAF (V600E) mutation

Oleaga Amelia , Goni Fernando , Ciriza Miguel Paja1, Maite Perez de , Etxeberria Eider , Calles Laura , Ugarte Estibaliz , Ugalde Aitziber , Elorza J Ramon

Introduction: BRAF (V600E) mutation is the most frequent detected genetic change in papillary thyroid cancer (PTC). Its presence has been related to aggressive clinical and pathological features. Therefore, BRAF mutation has drawn considerable interest as a potential prognostic factor for PTC. The presence of the mutation confers the tumour a disability to uptake RAI, diminishing the therapeutic tools. However if this feature is related to some kind of tumour dedifferentiation...